Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Jae Hyun Bae (Bae JH), Sunhee Kim (Kim S), Eun-Gee Park (Park EG), Sin Gon Kim (Kim SG), Seokyung Hahn (Hahn S), Nam Hoon Kim (Kim NH)
Endocrinol Metab. 2019;34(1):80-92.   Published online 2019 Mar 21     DOI: https://doi.org/10.3803/EnM.2019.34.1.80
Citations to this article as recorded by Crossref logo
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Christian W. Mende
Advances in Therapy.2022; 39(1): 148.     CrossRef
Management of Hyperglycemia in Older Adults with Type 2 Diabetes
Gunjan Y. Gandhi, Arshag D. Mooradian
Drugs & Aging.2022; 39(1): 39.     CrossRef
Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
Zhen Ruan, Huimin Zou, Qing Lei, Carolina Oi Lam Ung, Honghao Shi, Hao Hu
Expert Review of Pharmacoeconomics & Outcomes Research.2022; 22(4): 555.     CrossRef
Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
Hiroki Teragawa, Takeshi Morimoto, Yuichi Fujii, Tomohiro Ueda, Mio Sakuma, Michio Shimabukuro, Osamu Arasaki, Koichi Node, Takashi Nomiyama, Shinichiro Ueda
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 685.     CrossRef
Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
The Korean Journal of Internal Medicine.2022; 37(3): 502.     CrossRef
The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus
Wan-Chia Hsu, Chun-Sheng Lin, Jung-Fu Chen, Chih-Min Chang
Journal of Clinical Medicine.2022; 11(9): 2653.     CrossRef
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Hiroaki Yagyu, Hitoshi Shimano
Journal of Diabetes Investigation.2022;[Epub]     CrossRef
The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes
Daniel V. O'Hara, Thomas R. Parkhill, Sunil V. Badve, Min Jun, Meg J. Jardine, Vlado Perkovic
Diabetes, Obesity and Metabolism.2021; 23(3): 763.     CrossRef
Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD
Acaris Benetti, Flavia Letícia Martins, Letícia Barros Sene, Maria Heloisa M. Shimizu, Antonio C. Seguro, Weverton M. Luchi, Adriana C. C. Girardi
American Journal of Physiology-Renal Physiology.2021; 320(3): F285.     CrossRef
Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
Johannes F.E. Mann, Marcel H.A. Muskiet
Kidney International.2021; 99(2): 314.     CrossRef
Renoprotective Effects of DPP-4 Inhibitors
Daiji Kawanami, Yuichi Takashi, Hiroyuki Takahashi, Ryoko Motonaga, Makito Tanabe
Antioxidants.2021; 10(2): 246.     CrossRef
Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney
Paul E. Squires, Gareth W. Price, Ulrik Mouritzen, Joe A. Potter, Bethany M. Williams, Claire E. Hills
International Journal of Molecular Sciences.2021; 22(6): 2809.     CrossRef
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Endocrinology and Metabolism.2021; 36(2): 388.     CrossRef
Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
Jack Wei Chieh Tan, David Sim, Junya Ako, Wael Almahmeed, Mark E Cooper, Jamshed J Dalal, Chaicharn Deerochanawong, David Wei Chun Huang, Sofian Johar, Upendra Kaul, Sin Gon Kim, Natalie Koh, Alice Pik-Shan Kong, Rungroj Krittayaphong, Bernard Kwok, Bien
European Cardiology Review.2021;[Epub]     CrossRef
Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
Francesco Prattichizzo, Paola de Candia, Antonio Ceriello
Metabolism.2021; 120: 154799.     CrossRef
SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
Robert C. Stanton
Seminars in Nephrology.2021; 41(2): 85.     CrossRef
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Nina Vodošek Hojs, Sebastjan Bevc, Robert Ekart, Nejc Piko, Tadej Petreski, Radovan Hojs
Pharmaceuticals.2021; 14(6): 561.     CrossRef
Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus
Swayam Prakash Srivastava, Han Zhou, Ocean Setia, Alan Dardik, Carlos Fernandez‐Hernando, Julie Goodwin
Journal of the American Heart Association.2021;[Epub]     CrossRef
Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
Swayam Prakash Srivastava, Rohit Srivastava, Subhash Chand, Julie E. Goodwin
Pharmaceuticals.2021; 14(8): 751.     CrossRef
Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: A systematic review and meta-analysis
SaikatK Dalui, Raja Chakraverty, Nafisha Yasmin, Smita Pattanaik, Kaushik Pandit, Suparna Chatterjee
Indian Journal of Endocrinology and Metabolism.2021; 25(4): 283.     CrossRef
Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
Yueh-Ting Lee, Chien-Ning Hsu, Chung-Ming Fu, Shih-Wei Wang, Chiang-Chi Huang, Lung-Chih Li
Frontiers in Pharmacology.2021;[Epub]     CrossRef
The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease
Mishal Yousef Alqurashi, Khalid Faisal Alharthi, Abdulaziz Abdulrahman Alshehri, Yazeed Khalid Alharbi, Mohammad Abdulmunem Sanousi, Anas Abdullah Almazyed, Khulud Saeed Alghamdi, Sarah Musaad Alrashidi, Waad Abdullah Qaeed, Amjad Aedh Alasmari
Pharmacophore.2021; 12(3): 91.     CrossRef
Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
Zoi Kleinaki, Stella Kapnisi, Sofia-Andriani Theodorelou-Charitou, Ilias P. Nikas, Stavroula A. Paschou
Hormones.2020; 19(4): 467.     CrossRef
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy.2020; 11(2): 369.     CrossRef
Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang, Edward Chia-Cheng Lai
Cardiovascular Diabetology.2020;[Epub]     CrossRef
Novel therapeutic agents for the treatment of diabetic kidney disease
Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
Expert Opinion on Investigational Drugs.2020; 29(11): 1277.     CrossRef
Renal protection with glucagon-like peptide-1 receptor agonists
Martina Vitale, Jonida Haxhi, Tiziana Cirrito, Giuseppe Pugliese
Current Opinion in Pharmacology.2020; 54: 91.     CrossRef
Loss of Mitochondrial Control Impacts Renal Health
Swayam Prakash Srivastava, Keizo Kanasaki, Julie E. Goodwin
Frontiers in Pharmacology.2020;[Epub]     CrossRef
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Scientific Reports.2019;[Epub]     CrossRef